<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Anti-epidermal growth factor receptor (EGFR) target therapies like <z:chebi fb="0" ids="114785">erlotinib</z:chebi> for metastatic <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> and cetuximab or panitumumab for <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) cause skin reaction that seems to be related to treatment efficacy </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C1167791" disease_type="Disease or Syndrome" abbrv="">Skin toxicity</z:e> evaluation protocol with panitumumab study has shown that preemptive treatment reduces the incidence of ≥Grade 2 (G2) <z:e sem="disease" ids="C1167791" disease_type="Disease or Syndrome" abbrv="">skin toxicity</z:e> in mCRC treated with panitumumab </plain></SENT>
<SENT sid="2" pm="."><plain>Aim of this study is to evaluate if preemptive <z:e sem="disease" ids="C1167791" disease_type="Disease or Syndrome" abbrv="">skin toxicity</z:e> treatment with different drugs has good efficacy in patients receiving anti-EGFR therapies, such as cetuximab, panitumumab, and <z:chebi fb="0" ids="114785">erlotinib</z:chebi>, for mCRC and metastatic <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Treatment included skin moisturizers with sunscreen and lymecycline 300 mg/daily </plain></SENT>
<SENT sid="4" pm="."><plain>Primary objective is to reduce the incidence of ≥G2 <z:e sem="disease" ids="C1167791" disease_type="Disease or Syndrome" abbrv="">skin toxicity</z:e> during the first 3 months of therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Toxicities are reported with confidence interval at 95 % </plain></SENT>
<SENT sid="6" pm="."><plain>Quality of life was assessed with Dermatology Life Quality Index every 2 weeks and evaluated with repeated measure ANOVA </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Fifty-one patients with mCRC (60.8 %) and metastatic <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> (39.2 %) were enrolled </plain></SENT>
<SENT sid="8" pm="."><plain>Anticancer drugs were <z:chebi fb="0" ids="114785">erlotinib</z:chebi>/cetuximab/panitumumab 20:30:1 </plain></SENT>
<SENT sid="9" pm="."><plain>At 3-month evaluation, 27.4 % patients had =G2 <z:e sem="disease" ids="C1167791" disease_type="Disease or Syndrome" abbrv="">skin toxicity</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="C1167791" disease_type="Disease or Syndrome" abbrv="">Skin toxicity</z:e> was not related with age (p = 0.67), sex (p = 0.65), previous chemotherapy regimens (p = 0.41), and current anti-EGFR treatment (p = 0.22) </plain></SENT>
<SENT sid="11" pm="."><plain>No gastrointestinal or hematological toxicities related to lymecycline were observed </plain></SENT>
<SENT sid="12" pm="."><plain>Only six patients required further drugs </plain></SENT>
<SENT sid="13" pm="."><plain>Quality of life analysis did not show a significant difference from the beginning and the end of treatment </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: Data show efficacy of preemptive treatment with a well-tolerated profile </plain></SENT>
<SENT sid="15" pm="."><plain>A reduction of severe <z:e sem="disease" ids="C1167791" disease_type="Disease or Syndrome" abbrv="">skin toxicities</z:e> is shown with an increase of grade 1 toxicities, not leading to anti-EGFR dose reduction and with better quality of life for patients </plain></SENT>
</text></document>